Review
The P-glycoprotein multidrug transporter

https://doi.org/10.1016/S0306-3623(96)00081-XGet rights and content

Abstract

  • 1.

    1. P-glycoprotein (P-gp) is a transmembrane protein involved in ATP-dependent efflux of various structurally unrelated anticancer drugs. Its overexpression in cancer cells decreases intracellular drug concentrations and, thus, confers a multidrug resistance phenotype.

  • 2.

    2. P-gp is encoded by MDR genes, which constitute a small gene family comprising two genes in humans and three genes in rodents. Only the MDR1 gene in humans and mdrl and mdr3 genes in rodents have been demonstrated to be involved in drug resistance.

  • 3.

    3. P-gp encoded by the human MDR1 gene is a phosphorylated and glycosylated protein 1289 amino acids long, and consists of 2 halves that share a high degree of similarity.

  • 4.

    4. A wide variety of cancers have been shown to express P-gp, including solid tumors and hematological malignancies. This P-gp positivity can be evidenced at the time of diagnosis prior to chemotherapy or at relapse after treatment, and has been correlated with treatment failure and poor prognosis in several types of cancer. In addition, P-gp is also expressed by some normal tissues, such as liver and kidney.

  • 5.

    5. P-gp expression is regulated by various factors, including xenobiotics and hormones.

  • 6.

    6. P-gp-mediated multidrug resistance can be reversed by various unrelated compounds called chemosensitizers or reversing agents. These drugs act through inhibition of P-gp function and have entered clinical trials.

References (157)

  • M.M. Cornwell et al.

    SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity

    J. Biol. Chem.

    (1993)
  • M.M. Cornwell et al.

    A signal transduction pathway for activation of the mdrl promoter involves the proto-oncogene c-raf kinase

    J. Biol. Chem.

    (1993)
  • S.J. Currier et al.

    Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters

    J. Biol. Chem.

    (1992)
  • C. Cuvier et al.

    Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance

    Biochem. Pharmacol.

    (1992)
  • K. Danö

    Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells

    Biochim. Biophys. Acta

    (1973)
  • B. Drenou et al.

    Detection of P-glycoprotein activity in normal and leukemic CD34 positive cells

    Leukemia Res.

    (1993)
  • O. Fardel et al.

    Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes

    FEBS Lett.

    (1993)
  • O. Fardel et al.

    Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells

    Biochem. Pharmacol.

    (1995)
  • S.J. Foote et al.

    Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum

    Cell

    (1989)
  • J.E. Goasguen et al.

    Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications

    Blood

    (1993)
  • M.E. Goldsmith et al.

    A Y-box consensus is required for basal expression of the human multidrug resistance (mdrl) gene

    J. Biol. Chem.

    (1993)
  • T.M. Grogan et al.

    P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy

    Blood

    (1993)
  • W.N. Hait et al.

    Rational design and preclinical pharmacology of drugs for reversing multidrug resistance

    Biochem. Pharmacol.

    (1992)
  • C.F. Higgins et al.

    Is the multidrug transporter a flippase?

    Trends Biochem. Sci.

    (1992)
  • B. Joly et al.

    Selective drug transport and P-glycoprotein activity in an in vitro blood-brain barrier model

    Tox. In Vitro

    (1995)
  • N. Kioka et al.

    Heat-shock responsive elements in the induction of the multidrug resistance gene (MDR1)

    FEBS Lett.

    (1992)
  • Y. Kobayashi et al.

    Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK 16 monoclonal antibody and AHC-52

    Biochem. Pharmacol.

    (1994)
  • K. Kohno et al.

    The direct activation of human multidrug resistance gene (MDR1) by anticancer agents

    Biochem. Biophys. Res. Commun.

    (1989)
  • V. Lecureur et al.

    The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function

    FEBS Lett.

    (1994)
  • J.P. Marie et al.

    Multidrug resistance (mdr 1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

    Blood

    (1991)
  • E.H. Abraham et al.

    The multidrug resistance (mdrl) gene product functions as an ATP channel

  • S.V. Ambudkar et al.

    Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis

  • S. Arao et al.

    Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer

    Cancer Res.

    (1994)
  • R.J. Arceci et al.

    The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus

  • R.J. Arceci et al.

    Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus

    Mol. Reprod. Dev.

    (1990)
  • M. Azzaria et al.

    Discrete mutations introduced in the predicted nucleotide-binding sites of the mdrl gene abolish its ability to confer multidrug resistance

    Mol. Cell. Biol.

    (1989)
  • S.E. Bates et al.

    Expression of a drug resistance gene in human neuroblastoma cellines: modulation by retinoic acid-induced differentiation

    Mol. Cell. Biol.

    (1989)
  • S.E. Bates et al.

    Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate

    Biochemistry

    (1992)
  • S.E. Bates et al.

    Differential modulation of P-glycoprotein transport by protein kinase inhibition

    Biochemistry

    (1993)
  • W.T. Beck et al.

    Continued expression of Vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase

    Cancer Res.

    (1982)
  • J.L. Biedler et al.

    Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies

    Cancer Res.

    (1970)
  • J. Bourhis et al.

    Correlation of MDR1 gene expression with chemotherapy in neuroblastoma

    J. Natl. Cancer Inst.

    (1989)
  • R.K. Burt et al.

    Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics

    J. Natl. Cancer Inst.

    (1988)
  • R.K. Burt et al.

    Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals

    Carcinogenesis

    (1988)
  • D.F. Callen et al.

    Localization of the human multiple drug resistance gene, MDR1, to 7q21.1

    J. Hum. Genet.

    (1987)
  • T.C. Chambers et al.

    Regulation by phorbol ester and protein kinase C inhibitors and by a protein phosphatase inhibitor (okadaic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cell

    Mol. Pharmacol.

    (1992)
  • H.S.L. Chan et al.

    Immunohisto-chemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

    J. Clin. Oncol.

    (1990)
  • P.M. Chaudhary et al.

    Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists

    Oncology Res.

    (1992)
  • P.M. Chaudhary et al.

    Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs

    J. Natl. Cancer Inst.

    (1993)
  • G. Chen et al.

    Prevalence of multidrug resistance related to activation of the mdrl gene in human sarcoma mutants derived by single-step doxorubicin selection

    Cancer Res.

    (1994)
  • View full text